Optimizing drug therapy in patients with cardiovascular disease: The impact of pharmacist-managed pharmacotherapy clinics in a primary care setting

Pharmacotherapy

Volumn 22, Issue 6, 2002, Pages 738-747

  Geber, Jean ^a   Parra, David ^a   Beckey, Nick P ^a,b,c   Korman, Lisa ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN; ANTICOAGULANT AGENT; ATORVASTATIN; CLOPIDOGREL; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; WARFARIN;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DRUG THERAPY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METHODOLOGY; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACIST; RETROSPECTIVE STUDY; CLINICAL PHARMACY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART EJECTION FRACTION; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; STATISTICAL ANALYSIS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PHARMACISTS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0036014878     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.9.738.34061     Document Type: Article

References (34)

1. Patterns of aspirin use in middle-aged adults: The atherosclerosis risk in communities (ARIC) study
2. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
3. Management of hypercholesterolemia: Practice patterns for primary care providers and cardiologists
4. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
5. Risk reduction therapies for patients with coronary artery disease: A call for increased implementation
6. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995
7. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure
8. Pharmacologic management of heart failure among older adults by office-based physicians in the United States
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
11. Risk factor modification: Rationale for management of dyslipidemia
12. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials
13. Serum cholesterol levels are underevaluated and undertreated
14. Overview of atherosclerosis
15. Management of patients with chronic stable angina at low risk for serious cardiac events
16. Executive summary of the third report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
17. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes
18. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects
19. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS)
20. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
21. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
22. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
23. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
24. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
25. Temporal trend in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995
26. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial. The assessment of treatment with lisinopril and survival
27. Outcome analysis of a pharmacist-managed anticoagulation service
28. Comparison of an anticoagulation clinic with usual medical care
29. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study
30. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit
31. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patient with hypercholesterolemia (the CURVES study)
32. Effectiveness of chart prompts improve physician compliance with the national cholesterol education program guidelines
33. Effects of computer-based clinical decision support systems on physician performance and patient outcomes